Imaging of Primary or Recurrent Breast Cancer With 18F-FluorThanatrace PET/CT

Active, not recruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

February 11, 2019

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2027

Conditions
Breast Cancer
Interventions
DRUG

Imaging Drug FluorThanatrace (FTT)

\[18F\]FTT is an investigational radioactive PET drug used to see PARP-1 activity in tumors. This radioactive imaging drug is injected into the body to see how it goes into places where there is active breast cancer. Using an imaging scan called Positron Emission Tomography (PET/CT), the radioactive drug can be seen in the body.

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

University of Pennsylvania

OTHER

NCT03846167 - Imaging of Primary or Recurrent Breast Cancer With 18F-FluorThanatrace PET/CT | Biotech Hunter | Biotech Hunter